Focus: Cancer Center Featured Story 2

• share
• favorite_border

• share
• favorite_border

Immunotherapy continues to revolutionize the field of non–small cell lung cancer (NSCLC), with researchers now focusing on the optimal use of immune agents in the frontline setting.

• share
• favorite_border

New data presented at a cancer conference suggests that more than three in five Australian breast cancer survivors are overweight or obese – and that it’s likely to increase their risk of cancer returning.

• share
• favorite_border

Researchers leading the largest genomic tumor profiling effort of its kind say such studies are technically feasible in a broad population of adult and pediatric patients with many different types of cancer.

• share
• favorite_border

Glioblastoma multiforme remains the most common and highly lethal brain cancer and is known for its ability to relapse.

• share
• favorite_border

Researchers are studying a new injectable chemo that has shown to be successful in canines.

• share
• favorite_border

Prediction model created by "research parasites" published today in Lancet Oncology offers a more accurate prognosis for a patient's metastatic castration-resistant prostate cancer

• share
• favorite_border

Aiming to further propel scientific discovery as well as augment and expand comprehensive cancer services for patients through collaborative efforts with Rutgers and RWJBarnabas Health, Steven K. Libutti, MD, FACS, has been named as the new Director of Rutgers Cancer Institute of New Jersey and will serve as Vice Chancellor for Cancer Programs for Rutgers Biomedical and Health Sciences at Rutgers University.

• share
• favorite_border

Fred Hutchinson Cancer Research Center and its patient care partner, Seattle Cancer Care Alliance, today announced that Lynne Kornblatt will be the organizations’ new vice president and chief human resources officer effective Jan. 3.

• share
• favorite_border

Providing access to NCCN Templates® through Cerner’s PowerChart Oncology™ will help practitioners make informed treatment decisions based on up-to-date, standard protocols

• share
• favorite_border

An experimental kidney cancer drug outperformed the standard first-line therapy for patients with metastatic disease who are considered at risk for poorer than average outcomes, according to results of a randomized phase II clinical trial by researchers at Dana-Farber Cancer Institute.

• share
• favorite_border

Astronauts survive in space by wearing high-tech space suits. But how do brain cancer cells thrive when they migrate to inhospitable sites within the brain?

• share
• favorite_border

New nursing leader named at Dana-Farber Cancer Institute. Anne Gross to start in new role on December 1, 2016.

• share
• favorite_border

Researchers from Moffitt Cancer Center’s Integrated Mathematical Oncology (IMO) Department are overcoming the limitations of common preclinical experiments and clinical trials by studying cancer through mathematical modeling.

• share
• favorite_border

When female employees of a mystery shopping firm called posing as 17-year-olds interested in tanning, 81 percent of indoor tanning facilities complied with the Texas ban on indoor tanning for those under the age of 18 in a study conducted by The University of Texas MD Anderson Cancer Center.

• share
• favorite_border

A Ludwig Cancer Research study shows that an experimental drug currently in clinical trials can reverse the effects of troublesome cells that prevent the body’s immune system from attacking tumors.

• share
• favorite_border

Hawaii Pacific Health has joined the Seattle Cancer Care Alliance Affiliate Network. SCCA has 13 Affiliate Network partners located across the Western U.S., including in Alaska, Idaho, Montana, Oregon, Washington, and now Hawaii.

• share
• favorite_border

Since 1941, when the Texas Legislature established the state’s first cancer hospital, The University of Texas MD Anderson Cancer Center has been a beacon of hope for more than 1.1 million patients.

• share
• favorite_border

Using prominent, graphic pictures on cigarette packs warning against smoking could avert more than 652,000 deaths, up to 92,000 low birth weight infants, up to 145,000 preterm births, and about 1,000 cases of sudden infant deaths in the U.S. over the next 50 years, say researchers from Georgetown Lombardi Comprehensive Cancer Center.

• share
• favorite_border

A paper published today in Science shows that smoking tobacco causes added mutations in the DNA of lung cells and in the DNA of other cells in the body. This is the first study to show the process by which smoking causes these cancers.

• share
• favorite_border

A Rutgers Cancer Institute of New Jersey researcher has received a $200,000 Grant from The V Foundation for Cancer Research to explore signaling in a cell pathway in triple-negative breast cancer.

• share
• favorite_border

Stanton L. Gerson, MD, director of the Case Comprehensive Cancer Center, in Cleveland, is the new president of the Association of American Cancer Institutes (AACI). His presidential initiative aims to improve patient outcomes and health care value in the community.

• share
• favorite_border

Researchers at The University of Texas MD Anderson Cancer Center have developed a new personalized assessment tool that could better predict lung cancer risk in never, light and heavy smokers using a large Taiwanese prospective cohort study.

• share
• favorite_border

As published in JNCCN, a recent project out of Canada shows that programs identifying stress and distress in patients with cancer increase health care professionals’ confidence and awareness of patient-centeredness; outcomes are influenced by site-based navigators and practice size.

• share
• favorite_border

Fred Hutchinson Cancer Research Center today announced the official opening of a first-of-its-kind clinic dedicated to providing innovative immunotherapies for cancer patients in clinical trials.

• share
• favorite_border

When it comes to prostate cancer biopsies, risk and reality don’t always match up, according to research published online today in the Journal of Clinical Oncology. Investigators from SWOG, the cancer clinical trials network funded by the National Cancer Institute (NCI), found widespread detection bias after a fresh examination of data from the two largest prostate cancer prevention trials ever conducted in the United States.

• share
• favorite_border

University of Colorado Cancer Center study published in the journal Gynecologic Oncology shows that only 44 percent of patients in a large, national sample received all three components of standard-of-care treatment, most often lacking brachytherapy.

• share
• favorite_border

Jennifer Klemp, PhD, MPH, director of cancer survivorship and an associate professor at The University of Kansas Cancer Center, is interviewed by Oncology Nursing News. In this interview, Klemp offers insights on some of the critical issues that clinicians face, among them: how to deliver optimal survivorship care, what ingredients go into the plan, how to measure progress, and how is this care reimbursed.

• share
• favorite_border

• share
• favorite_border

• share
• favorite_border

The FDA granted approval to pembrolizumab for the first-line treatment of patients with metastatic non–small cell lung cancer whose tumors express programmed death ligand-1 as determined by an FDA–approved test.

• share
• favorite_border

The recent approval of pembrolizumab (Keytruda) in recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) following progression on a platinum-based chemotherapy was a significant advancement for the disease. However, Barbara A. Burtness, MD, said, the approval of the PD-1 inhibitor only scratches the surface of the potential of immunotherapies in head and neck cancer.

• share
• favorite_border

• share
• favorite_border

Acute myeloid leukemia (AML) is an aggressive cancer known for drug resistance and relapse. In an effort to uncover new treatment strategies, researchers at University of California San Diego School of Medicine and Moores Cancer Center discovered that a cell surface molecule known as CD98 promotes AML. The study also shows that inhibiting CD98 with the therapeutic antibody IGN523 blocks AML growth in patient-derived cells and mouse models.

• share
• favorite_border

University of Colorado Cancer Center study shows that comparing cancer cell sequencing results to published reference genomes may be less accurate than comparing to healthy cell from same organism.

• share
• favorite_border

The University of Texas MD Anderson Cancer Center’s Institute for Applied Cancer Science (IACS) has initiated the first clinical study of a novel drug designed to starve cancer cells, IACS-10759.

• share
• favorite_border

Spurred by NYS Trade Mission to Cuba in 2015, Buffalo cancer center will conduct a clinical trial with CIMAvax-EGF, groundbreaking immunotherapy for lung cancer developed in Cuba — becoming the first American center to receive FDA authorization to sponsor a clinical trial offering a Cuban-made therapy to U.S. patients — and will work to speed this and other innovative therapies to patients worldwide through a historic new business venture with Cuban research institute

• share
• favorite_border

A Rutgers Cancer Institute of New Jersey researcher has received a $596,250 award (W81XWH-16-1-0358) from the U.S. Department of Defense to study the role of chronic stress in breast cancer development. The focus of the work is to explore how chronic stress impacts breast cancer risk and to provide a foundation that can guide prevention strategies.

• share
• favorite_border

Patients with disseminated advanced cancer who undergo surgery are far more likely to endure long hospital stays and readmissions, referrals to extended care facilities and death, UC Davis researchers have found.

• share
• favorite_border

Painful sex in women after cancer treatment is relatively common, often treatable and needs to be addressed by medical providers, a UC Davis oncologist and researcher suggests.

• share
• favorite_border

A team of researchers led by UC San Francisco scientists has identified a new drug target for triple-negative breast cancer, an aggressive disease subtype that has the poorest outcomes and accounts for as many as one in five cases. The findings are particularly noteworthy because drugs that act on the newly discovered target, a protein known as PIM1, are already in clinical trials for leukemia and multiple myeloma.

• share
• favorite_border

Tonya Edwards, a clinical nurse in Palliative Care at The University of Texas MD Anderson Cancer Center, is the recipient of the 2016 Brown Foundation Award for Excellence in Oncology Nursing.

• share
• favorite_border

José R. Conejo-Garcia, M.D., Ph.D. has joined Moffitt Cancer Center as co-leader of the Immunology Program and chair of the Department of Immunology.

• share
• favorite_border

A Ludwig Cancer Research study published in the current issue of Scientific Reports describes a new method and risk model to assess how aggressive a bladder cancer is likely to be. “If confirmed in larger studies, our findings could help physicians get a better handle on how a patient’s bladder cancer is likely to progress and allow them to personalize treatment on the basis of that knowledge,” said Ralph Weichselbaum, director of the Ludwig Center at Chicago University, who led the study.

• share
• favorite_border

Understanding how multiple myeloma develops and responds to therapies may be easier using a new mouse model developed at Yale University School of Medicine. The model supports the growth of cells derived from patients with multiple myeloma or the disease’s precursor states.

• share
• favorite_border

Researchers at the Yale School of Medicine have identified a chemical inhibitor that limits the growth of lung tumor cells. The inhibitor works by partially disrupting glycosylation, the addition of sugar chains to proteins.

• share
• favorite_border

• share
• favorite_border

• share
• favorite_border

In a recent study, senior author and Yale pathology professor Wang Min demonstrated that the tumors release substances called cytokines to attract macrophages.

• share
• favorite_border

Cancer Moonshot Task Force Executive Director Greg Simon will speak at the 2016 AACI/CCAF Annual Meeting on Tuesday, October 25, in Chicago.